Payment overview · 2025
General Payments
$935.47
39 reported records · 13 companies
Healthcare provider profile · identity verified
Firas Aubeid, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NEW LENOX, IL · NPI 1760771968
Verified facts
What the public records show
CMS Open Payments records show Firas Aubeid, M.D. received $935.47 in general payments during 2025 across 39 reported records.
PFIZER INC. accounted for 15.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 324 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $141.78 | 15.2% | 9 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $132.80 | 14.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $129.01 | 13.8% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $106.85 | 11.4% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $105.14 | 11.2% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $93.79 | 10.0% | 5 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $84.63 | 9.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $49.62 | 5.3% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $27.15 | 2.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.94 | 2.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.53 | 1.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.98 | 1.6% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.25 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $935.47 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $141.78 | 9 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $132.80 | 1 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $129.01 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $106.85 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $106.85 | 5 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $84.63 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $75.85 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $73.03 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $73.03 | 4 | 2025 |
Source payment records
|
|||||
| DELSTRIGO Normalized: delstrigo |
Drug | Merck Sharp & Dohme LLC | $59.32 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $49.62 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $36.47 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $33.01 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $32.11 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $27.15 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.20 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $14.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 324 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 51 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 42 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 49 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 53 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
51 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
53 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
49 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
324 | 81 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1148 | 238 |
| Amlodipine Besylate | Amlodipine Besylate | 658 | 145 |
| Levothyroxine Sodium | Levothyroxine Sodium | 424 | 97 |
| Losartan Potassium | Losartan Potassium | 404 | 101 |
| Metoprolol Succinate | Metoprolol Succinate | 400 | 94 |
| Gabapentin | Gabapentin | 377 | 83 |
| Metformin Hcl | Metformin Hcl | 325 | 71 |
| Eliquis | Apixaban | 324 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 308 | 103 |
| Furosemide | Furosemide | 289 | 96 |
| Escitalopram Oxalate | Escitalopram Oxalate | 261 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 251 | 44 |
| Lisinopril | Lisinopril | 229 | 63 |
| Hydralazine Hcl | Hydralazine Hcl | 223 | 40 |
| Carvedilol | Carvedilol | 211 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 201 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 193 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 193 | 57 |
| Allopurinol | Allopurinol | 175 | 44 |
| Potassium Chloride | Potassium Chloride | 166 | 41 |
| Omeprazole | Omeprazole | 163 | 43 |
| Trazodone Hcl | Trazodone Hcl | 140 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 133 | 50 |
| Sertraline Hcl | Sertraline Hcl | 131 | 31 |
| Donepezil Hcl | Donepezil Hcl | 127 | 17 |
| Nifedipine Er | Nifedipine | 117 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 110 | 45 |
| Cefdinir | Cefdinir | 105 | 86 |
| Simvastatin | Simvastatin | 104 | 32 |
| Mirtazapine | Mirtazapine | 102 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 101 | 16 |
| Alprazolam | Alprazolam | 99 | 30 |
| Montelukast Sodium | Montelukast Sodium | 99 | 25 |
| Midodrine Hcl | Midodrine Hcl | 93 | 19 |
| Meloxicam | Meloxicam | 92 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 87 | 74 |
| Prednisone | Prednisone | 87 | 40 |
| Methylprednisolone | Methylprednisolone | 79 | 69 |
| Oxybutynin Chloride | Oxybutynin Chloride | 79 | suppressed |
| Glipizide | Glipizide | 78 | 18 |
| Alendronate Sodium | Alendronate Sodium | 77 | 23 |
| Levetiracetam | Levetiracetam | 75 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 22 |
| Olanzapine | Olanzapine | 70 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 68 | 42 |
| Lorazepam | Lorazepam | 68 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 18 |
| Famotidine | Famotidine | 66 | 26 |
| Januvia | Sitagliptin Phosphate | 65 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 29 |
| Clonidine Hcl | Clonidine Hcl | 62 | 12 |
| Baclofen | Baclofen | 61 | 14 |
| Xarelto | Rivaroxaban | 61 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 59 | 15 |
| Lovastatin | Lovastatin | 59 | 12 |
| Tramadol Hcl | Tramadol Hcl | 59 | 24 |
| Enalapril Maleate | Enalapril Maleate | 53 | 19 |
| Memantine Hcl | Memantine Hcl | 53 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | 18 |
| Farxiga | Dapagliflozin Propanediol | 51 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | 13 |
| Azithromycin | Azithromycin | 49 | 44 |
| Bumetanide | Bumetanide | 49 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 49 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 46 |
| Ezetimibe | Ezetimibe | 49 | 19 |
| Ozempic | Semaglutide | 49 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | 15 |
| Clonazepam | Clonazepam | 47 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 47 | 12 |
| Spironolactone | Spironolactone | 47 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | suppressed |
| Amantadine | Amantadine Hcl | 44 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 43 | suppressed |
| Jardiance | Empagliflozin | 42 | 12 |
| Valsartan | Valsartan | 42 | 16 |
| Finasteride | Finasteride | 41 | 14 |
| Enoxaparin Sodium | Enoxaparin Sodium | 40 | suppressed |
| Clozapine | Clozapine | 39 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 39 | 20 |
| Warfarin Sodium | Warfarin Sodium | 38 | 11 |
| Torsemide | Torsemide | 37 | 11 |
| Lamotrigine | Lamotrigine | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 20 |
| Digoxin | Digoxin | 35 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | suppressed |
| Sucralfate | Sucralfate | 34 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 33 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 32 | suppressed |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | 16 |
| Diltiazem Hcl | Diltiazem Hcl | 30 | suppressed |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Nystatin | Nystatin | 30 | 17 |
| Glimepiride | Glimepiride | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 21 |
| Meclizine Hcl | Meclizine Hcl | 28 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Celecoxib | Celecoxib | 23 | 11 |
| Cephalexin | Cephalexin | 23 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | 13 |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | 15 |
| Terbinafine Hcl | Terbinafine Hcl | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 16 |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Clonidine | Clonidine | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 16 |
| Vancomycin Hcl | Vancomycin Hcl | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Scopolamine | Scopolamine | 16 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Nexletol | Bempedoic Acid | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Octreotide Acetate | Octreotide Acetate | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Calcium Acetate | Calcium Acetate | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $935.47 · 39 records | PFIZER INC. | AREXVY, CONTRAVE, CREON, DELSTRIGO, Da Vinci Surgical System, ELIQUIS, ENTRESTO, FARXIGA, JARDIANCE, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, Ozempic, PIFELTRO, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, Tymlos, ZAVZPRET, ZEPBOUND, ZORYVE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error